{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:35:39Z","timestamp":1794440139175,"version":"4.9.1"},"reference-count":71,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.1001\/jamacardio.2021.2241","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T19:49:13Z","timestamp":1625687353000},"page":"1329","source":"Crossref","is-referenced-by-count":170,"title":["Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor\u2013Associated Myocarditis"],"prefix":"10.1001","volume":"6","author":[{"given":"Lorenz H.","family":"Lehmann","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology, and Pneumology, Cardio-Oncology Unit, Heidelberg University Hospital, Heidelberg, Germany"},{"name":"German Centre for Cardiovascular Research, partner site Heidelberg\/Mannheim, Heidelberg, Germany"},{"name":"German Cancer Research Centre, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cautela","sequence":"additional","affiliation":[{"name":"Aix-Marseille University, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, Center for Cardiovascular and Nutrition Research, Nord Hospital, Assistance Publique-H\u00f4pitaux de Marseille, France"},{"name":"Groupe M\u00e9diterran\u00e9en de Cardio-Oncologie, Marseille, France"},{"name":"Oncosafety Network of the Early Phases Cancer Trials Center, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Palaskas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Baik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Sorbonne Universit\u00e9, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, Paris, France"},{"name":"Sorbonne Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Normandie University, University of Caen Normandy, PICARO Cardio-oncology Program, Signalisation, \u00c9lectrophysiologie et Imagerie des L\u00e9sions d'Isch\u00e9mie-Reperfusion Myocardique, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Kiel, Kiel, Germany"},{"name":"German Center for Cardiovascular Research, partner site Hamburg\/Kiel\/L\u00fcbeck, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar","family":"Aras","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti H.","family":"Asnani","sequence":"additional","affiliation":[{"name":"CardioVascular Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Laufer-Perl","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Thuny","sequence":"additional","affiliation":[{"name":"Aix-Marseille University, University Mediterranean Center of Cardio-Oncology, Unit of Heart Failure and Valvular Heart Diseases, Center for Cardiovascular and Nutrition Research, Nord Hospital, Assistance Publique-H\u00f4pitaux de Marseille, France"},{"name":"Groupe M\u00e9diterran\u00e9en de Cardio-Oncologie, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Kerneis","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, ACTION Study Group, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Institut de Cardiologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (Assistance Publique-H\u00f4pitaux de Paris), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Hayek","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Universitaires Paris-Est, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Saint Antoine, Service de Cardiologie, Unico, Unit\u00e9 de Cardio-Oncologie, Groupe de Recherche Clinique en Cardio-Oncologie, Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Department of Pharmacology, Sorbonne Universit\u00e9, Assistance Publique-H\u00f4pitaux de Paris, UNICO-GRECO Cardio-Oncology Program, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"hrv210002r1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","article-title":"Immuno-oncology drug development goes global.","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"hrv210002r2","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors.","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"hrv210002r3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.01.028","article-title":"Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.","volume":"130","author":"Yang","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"hrv210002r4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"hrv210002r5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study.","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"issue":"12","key":"hrv210002r6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"hrv210002r7","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1016\/S1470-2045(20)30107-8","article-title":"Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.","volume":"21","author":"Johnson","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"hrv210002r8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"hrv210002r9","first-page":"292","article-title":"Myocarditis with immune checkpoint blockade.","volume":"376","author":"Moslehi","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"hrv210002r10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors.","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"hrv210002r11","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity.","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"hrv210002r12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"issue":"23","key":"hrv210002r14","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1161\/CIRCULATIONAHA.119.043171","article-title":"Heart-specific immune responses in an animal model of autoimmune-related myocarditis mitigated by an immunoproteasome inhibitor and genetic ablation.","volume":"141","author":"Bockstahler","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"hrv210002r15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"hrv210002r16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2019.07.025","article-title":"Diagnosis of immune checkpoint inhibitor-associated myocarditis: a systematic review.","volume":"296","author":"Pradhan","year":"2019","journal-title":"Int J Cardiol"},{"issue":"8","key":"hrv210002r17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"18","key":"hrv210002r18","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade.","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"hrv210002r19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors.","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"25","key":"hrv210002r20","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"hrv210002r21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"15","key":"hrv210002r22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies.","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"hrv210002r23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.","volume":"117","author":"Tay","year":"2017","journal-title":"Br J Cancer"},{"issue":"10","key":"hrv210002r24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with Anti-PD-1 antibody nivolumab.","volume":"9","author":"Tadokoro","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"1","key":"hrv210002r25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade.","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"8","key":"hrv210002r26","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action.","volume":"23","author":"Neilan","year":"2018","journal-title":"Oncologist"},{"key":"hrv210002r27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.11.026","article-title":"Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.","volume":"91","author":"Nasr","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"hrv210002r28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/CMR.0000000000000251","article-title":"Myocarditis as an immune-related adverse event with ipilimumab\/nivolumab combination therapy for metastatic melanoma.","volume":"26","author":"Mehta","year":"2016","journal-title":"Melanoma Res"},{"issue":"3","key":"hrv210002r29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/jfo.2018.63.issue-3","article-title":"Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab.","volume":"63","author":"Matson","year":"2018","journal-title":"J Forensic Sci"},{"key":"hrv210002r30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"hrv210002r31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"3","key":"hrv210002r33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-induced myocarditis concomitant with myasthenia gravis.","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"7","key":"hrv210002r34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.","volume":"56","author":"Chen","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"hrv210002r35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"issue":"3","key":"hrv210002r36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention.","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"hrv210002r37","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease.","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"issue":"1","key":"hrv210002r38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","article-title":"Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.","volume":"5","author":"John","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"7","key":"hrv210002r39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution.","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"hrv210002r40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"24","key":"hrv210002r41","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis.","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"hrv210002r42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","article-title":"Cardiovascular toxicities associated with cancer immunotherapies.","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"7","key":"hrv210002r43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11936-018-0649-4","article-title":"Cardiotoxicity of novel targeted chemotherapeutic agents.","volume":"20","author":"Rhea","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"2","key":"hrv210002r44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology.","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"hrv210002r45","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area.","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol"},{"issue":"5","key":"hrv210002r46","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1634\/theoncologist.2019-0040","article-title":"Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the Memorial Sloan Kettering Cancer Center Experience.","volume":"24","author":"Lee Chuy","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"hrv210002r47","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/eurheartj\/ehq456","article-title":"Troponin elevation in coronary vs. non-coronary disease.","volume":"32","author":"Agewall","year":"2011","journal-title":"Eur Heart J"},{"issue":"4","key":"hrv210002r48","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10741-014-9440-0","article-title":"A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods.","volume":"19","author":"Oremus","year":"2014","journal-title":"Heart Fail Rev"},{"issue":"6","key":"hrv210002r49","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"hrv210002r50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis.","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"hrv210002r51","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"Cardiovascular magnetic resonance in myocarditis: a JACC white paper.","volume":"53","author":"Friedrich","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"hrv210002r52","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hrv210002r53","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis.","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hrv210002r54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","article-title":"Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms.","volume":"33","author":"Champion","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"hrv210002r55","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCULATIONAHA.119.042276","article-title":"Cardio-immuno-oncology.","volume":"141","author":"Zaha","year":"2020","journal-title":"Circulation"},{"key":"hrv210002r56","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2020.107211","article-title":"Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: pathway toward precision-based therapy.","volume":"47","author":"Balanescu","year":"2020","journal-title":"Cardiovasc Pathol"},{"issue":"7","key":"hrv210002r57","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/ejhf.2019.21.issue-7","article-title":"Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication.","volume":"21","author":"Ederhy","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hrv210002r58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"hrv210002r59","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jacc.2019.05.026","article-title":"Fulminant myocarditis: evolving diagnosis, evolving biology, evolving prognosis.","volume":"74","author":"Moslehi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hrv210002r60","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"9","key":"hrv210002r61","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity.","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"hrv210002r62","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"hrv210002r63","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis.","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"hrv210002r64","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist.","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"issue":"6","key":"hrv210002r65","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1161\/CIR.0000000000000745","article-title":"Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association.","volume":"141","author":"Kociol","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"hrv210002r66","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy.","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"hrv210002r67","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","article-title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.","volume":"31","author":"Doms","year":"2020","journal-title":"Ann Oncol"},{"key":"hrv210002r68","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance.","author":"Geraud","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"hrv210002r69","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-020-01648-3","article-title":"Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.","author":"Peleg Hasson","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"9203","key":"hrv210002r70","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0140-6736(99)06290-X","article-title":"Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment.","volume":"355","author":"Henzen","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"hrv210002r71","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","article-title":"Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.","volume":"63","author":"Blankstein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"hrv210002r13","author":"Caforio","year":"2013"},{"key":"hrv210002r32","author":"Gibson","year":"2016"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2781842\/jamacardiology_lehmann_2021_rv_210002_1635348665.59463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T16:01:38Z","timestamp":1636387298000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2781842"}},"subtitle":["A Narrative Review"],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2021.2241","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}